Sentry Investment Management LLC Lowers Stock Holdings in Humana Inc. (NYSE:HUM)

Sentry Investment Management LLC trimmed its position in shares of Humana Inc. (NYSE:HUM) by 14.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 486 shares of the insurance provider’s stock after selling 79 shares during the quarter. Sentry Investment Management LLC’s holdings in Humana were worth $123,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. AMF Tjanstepension AB raised its position in Humana by 166.8% in the 3rd quarter. AMF Tjanstepension AB now owns 40,051 shares of the insurance provider’s stock valued at $12,686,000 after purchasing an additional 25,041 shares in the last quarter. Assenagon Asset Management S.A. raised its position in Humana by 12.7% in the 3rd quarter. Assenagon Asset Management S.A. now owns 4,090 shares of the insurance provider’s stock valued at $1,295,000 after purchasing an additional 461 shares in the last quarter. DekaBank Deutsche Girozentrale raised its position in Humana by 7.4% in the 3rd quarter. DekaBank Deutsche Girozentrale now owns 55,702 shares of the insurance provider’s stock valued at $17,652,000 after purchasing an additional 3,862 shares in the last quarter. Your Advocates Ltd. LLP raised its position in Humana by 81.8% in the 3rd quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock valued at $32,000 after purchasing an additional 45 shares in the last quarter. Finally, AustralianSuper Pty Ltd raised its position in Humana by 35.2% in the 3rd quarter. AustralianSuper Pty Ltd now owns 2,495 shares of the insurance provider’s stock valued at $790,000 after purchasing an additional 650 shares in the last quarter. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Humana Trading Down 1.6 %

Shares of HUM stock opened at $255.06 on Thursday. The business’s 50 day moving average is $270.12 and its two-hundred day moving average is $288.06. Humana Inc. has a twelve month low of $213.31 and a twelve month high of $406.46. The company has a market capitalization of $30.77 billion, a P/E ratio of 25.63, a price-to-earnings-growth ratio of 2.05 and a beta of 0.56. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68.

Humana (NYSE:HUM) last announced its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. Equities analysts forecast that Humana Inc. will post 16.47 EPS for the current year.

Humana Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be paid a $0.885 dividend. The ex-dividend date of this dividend is Friday, March 28th. This represents a $3.54 annualized dividend and a dividend yield of 1.39%. Humana’s dividend payout ratio (DPR) is currently 35.58%.

Insider Buying and Selling at Humana

In related news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the sale, the insider now directly owns 8,181 shares in the company, valued at $2,096,463.06. The trade was a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.32% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Wells Fargo & Company reduced their price target on Humana from $387.00 to $290.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. StockNews.com raised Humana from a “hold” rating to a “buy” rating in a research report on Tuesday. TD Cowen raised their target price on Humana from $261.00 to $268.00 and gave the stock a “hold” rating in a research report on Monday, November 4th. Cantor Fitzgerald reissued a “neutral” rating and set a $290.00 target price on shares of Humana in a research report on Wednesday, February 12th. Finally, Bank of America raised Humana from an “underperform” rating to a “neutral” rating and raised their target price for the stock from $247.00 to $308.00 in a research report on Wednesday, November 6th. Nineteen investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, Humana presently has an average rating of “Hold” and a consensus target price of $285.68.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.